Direct Answer
Gilead Sciences, Inc.'s SEC filings show revenue of $4.2 billion in fiscal 2007 and $29.4 billion in fiscal 2025, a compound annual growth rate of 11.4%. Its Form 8-K filings report one completed acquisition in that period (Immunomedics, Inc. in 2020).
Key Milestones
Company-history milestones are listed by year. Events from Gilead Sciences, Inc.'s SEC filing record are dated by the filing that reports them and link to it.
| Year | Milestone | Source |
|---|---|---|
| 1987 | Gilead was founded as a biotechnology company focused on antiviral science. | Company history |
| 1990 | The company built a major antiviral franchise through internal development, partnerships, and acquisitions. | Company history |
| 2011 | Gilead agreed to acquire Pharmasset, a pivotal step in the hepatitis C franchise that later transformed the company's earnings base. | Company history |
| 2017 | Gilead acquired Kite Pharma, establishing a cell-therapy platform in oncology. | Company history |
| 2020 | The company has continued to defend and expand its HIV franchise while investing heavily in oncology and other pipeline opportunities. | Company history |
| 2020 | Completed acquisition of Immunomedics, Inc. | Form 8-K filed October 23, 2020 |
How Has Gilead Sciences, Inc.'s Revenue Grown?
The fastest year was fiscal 2014, when revenue grew 122.2%. Revenue fell in five years: fiscal 2016 (-6.9%), fiscal 2017 (-14.1%), fiscal 2018 (-15.2%), fiscal 2022 (-0.1%) and fiscal 2023 (-0.6%); the 10-K for each of those years explains what drove it. Revenue first passed $5 billion in fiscal 2008, $10 billion in fiscal 2013 and $25 billion in fiscal 2015.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 ended December 31, 2025 | $29.4 billion | 2.4% |
| FY2024 ended December 31, 2024 | $28.8 billion | 6.0% |
| FY2023 ended December 31, 2023 | $27.1 billion | -0.6% |
| FY2022 ended December 31, 2022 | $27.3 billion | -0.1% |
| FY2021 ended December 31, 2021 | $27.3 billion | 10.6% |
| FY2020 ended December 31, 2020 | $24.7 billion | 10.0% |
| FY2019 ended December 31, 2019 | $22.4 billion | 1.5% |
| FY2018 ended December 31, 2018 | $22.1 billion | -15.2% |
| FY2017 ended December 31, 2017 | $26.1 billion | -14.1% |
| FY2016 ended December 31, 2016 | $30.4 billion | -6.9% |
| FY2015 ended December 31, 2015 | $32.6 billion | 31.1% |
| FY2014 ended December 31, 2014 | $24.9 billion | 122.2% |
| FY2013 ended December 31, 2013 | $11.2 billion | 15.5% |
| FY2012 ended December 31, 2012 | $9.7 billion | 15.7% |
| FY2011 ended December 31, 2011 | $8.4 billion | 5.5% |
| FY2010 ended December 31, 2010 | $7.9 billion | 13.4% |
| FY2009 ended December 31, 2009 | $7.0 billion | 31.4% |
| FY2008 ended December 31, 2008 | $5.3 billion | 26.1% |
| FY2007 ended December 31, 2007 | $4.2 billion | n/a |
How Do These Events Affect Gilead Sciences, Inc.'s Financial History?
Acquisitions and disposals break the comparison from one year to the next. Growth in fiscal 2020 and the year after mixes the existing business with what was bought or sold, so the 10-K's discussion of results, which usually separates the two, says more than the headline growth rate in those years.
Each year shows the revenue from the latest 10-K that reported it, so a year a company later restated can differ from the figure it first published, and most companies moved to a new revenue tag after the 2018 change in revenue accounting.
Where This Timeline Comes From
Revenue, stock splits and former names come from Gilead Sciences, Inc.'s filings with the SEC, read from EDGAR's XBRL company facts and submissions data on October 5, 2026. Acquisitions and disposals are those reported as completed under Item 2.01 of a Form 8-K in the filings EDGAR lists for the company, each checked against the filing itself. Milestones marked "Company history" summarize widely reported events and are dated by year only. This page is educational and describes history; it is not a forecast or a recommendation.
Frequently Asked Questions
How much has Gilead Sciences, Inc.'s revenue grown?
From $4.2 billion in fiscal 2007 to $29.4 billion in fiscal 2025, a compound annual growth rate of 11.4%, according to the revenue Gilead Sciences, Inc. reported in its Form 10-K filings.
What major acquisitions has Gilead Sciences, Inc. completed?
Gilead Sciences, Inc.'s Form 8-K filings report completing the acquisition of Immunomedics, Inc. (October 2020). Each is linked to its filing in the milestone table.
Has Gilead Sciences, Inc.'s revenue ever declined?
Yes, in fiscal 2016 (-6.9%), fiscal 2017 (-14.1%), fiscal 2018 (-15.2%), fiscal 2022 (-0.1%) and fiscal 2023 (-0.6%), based on the revenue reported in its 10-K filings.